Post-treatment Hematological Variations and the Role of Hemoglobin as a Predictor of Disease-free Survival in Stage 2 Breast Cancer Patients

Abstract

The primary objective of this study was to determine post-treatment variations in the hematological profile of stage 2 breast cancer patients and investigate the influence of disease stage and treatment pattern on these changes. The secondary objective was to evaluate the role of post-treatment hemoglobin as a predictor of disease-free survival. MethodsThis prospective, observational study included 177 stage 2, female, breast cancer patients. Treatment included surgery, chemotherapy, radiotherapy, and hormonal (antiestrogen) therapy. Patients were divided into treatment groups based on their histopathological features. Laboratory investigations, including hemoglobin and complete blood count, were carried out twice, first, at the initial cancer diagnosis and, second, eight weeks after completion of radiotherapy. The patients were followed for a period of four years and their disease-free survival was calculated.

A Cross-Sectional Study of Sialic Acids Level in Breast Cancer Patients Attending Ahmadu Bello University Teaching Hospital Zaria, North-Western Nigeria: Preliminary investigations and Implications on Disease Subtypes, Grade and Chemotherapy Courses

“…The study also found poor treatment outcomes in patients with persistently low levels of Hb (Lee et al, 2017). The observation that red blood cell (RBC) concentration was significantly lower among the patients agrees with a previous study that found significantly lower RBC levels in breast cancer patients (Raza et al, 2020). Considering the role of inflammation in breast cancer pathology (Colotta et al, 2009), inflammatory blood markers such as white blood cell count could have prognostic potential in breast cancer patients (Park et al, 2019).…”

“…Consequently, the development of models that utilize inflammatory blood parameters to predict treatment outcomes among breast cancer patients has been suggested (Zhu et al, 2021). Lower levels of Hb and RBC observed in breast cancer patients necessitate that treatment options consider possible anaemia in breast cancer patients, as some treatments could exacerbate anaemia (Raza et al, 2020). Ibrahim et a.l., 2022…”

A Prognostic Model Based on Clinicopathological Features and Inflammation- and Nutrition-Related Indicators Predicts Overall Survival in Surgical Patients With Tongue Squamous Cell Carcinoma

“… 20 , 35 RBC is an important nutrition-related prognostic factor for cancers and decreased RBC has been found to associate with poor survival in breast cancer and colorectal cancer. 36 , 37 In the present study, we also revealed that a reduced preoperative RBC level was an independent prognostic factor in TSCC.…”

Hematological abnormalities before and after initiation of cancer treatment among breast cancer patients attending at the University of Gondar comprehensive specialized hospital cancer treatment center

“…Hematological abnormalities can be observed both before and after cancer treatment. Pretreatment hematological abnormalities are mostly due to suppression of hematopoiesis via bone marrow infiltration [ 8 , 9 ]. Several studies confirm that pretreatment anemia, neutropenia, and thrombocytopenia were found to be common in breast cancer patients [ 10 , 11 ].…”